For the purpose of this audit, we have used the cutoff of 8 to determine prevalence of mild severity for both dimensions.
We suggest that AV-ECMO with cardiovascular support [ 30] could be suitable for use in ALI of mild severity, in which permissive hypercapnia is not an acceptable treatment [ 28, 31].
In Figure 6, we present this analysis for the mild severity scenario assuming uncertainty ranges of 0.2 0.5, 0.005 0.03, and 0.01 0.1 for p M| S, p H| M, and p D| H, respectively (for the other scenarios, see Web Figures 5 and 6).
All local PIRs were of mild severity.
Most illnesses were of mild severity (78%).
There was an inverse relationship between hypoglycemic symptom severity and patient-reported QOL, with patients reporting severe symptoms having a mean (SD) score of 54.30 18.777), compared with 65.80 16.922) for moderate and 70.93 15.566) for mild symptom severity, and 73.47 (16.11) for patients reporting no symptoms (p < 0.0001).
These costs were estimated at $6,096 per year for a patient with mild severity, $13,251 for moderate OA severity, and $17,214 for a patient with severe OA.
The utilization was lowest (13.83%) for those with very severe disability, whereas that was the highest (19.38%) for those with mild severity.
For example, compared with the severe scenario, the size of a case series would need to be 10- and 83-fold larger for the intermediate and mild severity scenarios, respectively, for a single-level sCFR estimator to have a similar coefficient of variation.
However, those differences are reduced when using the optimal pyramidal estimator in each scenario: One would then need 2.67- and 8-fold more cases for the intermediate and mild severity scenarios, respectively.
